SCHEDULE 13G/A 0001989492 XXXXXXXX LIVE 3 Common Stock, par value $0.005 per share 07/28/2025 0000748592 Ernexa Therapeutics Inc. 114082308 1035 Cambridge Stree Suite 18A Cambridge MA 02141 Rule 13d-1(c) IAF, LLC b SC 315779.00 0.00 315779.00 0.00 315779.00 N 4.1 OO Percentage of ownership in Row 11 is based on an aggregate of 7,670,889 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2025. This Amendment No. 3 amends the Schedule 13G filed by the Reporting Person named therein on December 20, 2023, as amended by Amendment No. 1 filed on February 12, 2025 and Amendment No. 2 filed on May 14, 2025. This Amendment No. 3 is being filed to report that the Reporting Person has ceased to be the beneficial owner of more than five percent of the outstanding shares of common stock of the Issuer and constitutes an "exit filing" for the Reporting Person. Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 IAF, LLC c/o 115 Church Street, Charleston, South Carolina 29401 South Carolina Y See Row 9 of the Reporting Person's cover page to this Schedule 13G. See Row 11 of the Reporting Person's cover page to this Schedule 13G. See Row 5 of the Reporting Person's cover page to this Schedule 13G. See Row 6 of the Reporting Person's cover page to this Schedule 13G. See Row 7 of the Reporting Person's cover page to this Schedule 13G. See Row 8 of the Reporting Person's cover page to this Schedule 13G. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. IAF, LLC /s/ Edward Bennett 08/18/2025